Hsbc Holdings PLC trimmed its stake in GSK plc (NYSE:GSK – Free Report) by 5.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,552,119 shares of the pharmaceutical company’s stock after selling 220,909 shares during the period. Hsbc Holdings PLC owned 0.17% of GSK worth $138,177,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Register Financial Advisors LLC bought a new position in shares of GSK in the 1st quarter worth $31,000. Ashton Thomas Private Wealth LLC bought a new position in shares of GSK in the 2nd quarter worth $37,000. Richardson Financial Services Inc. bought a new position in shares of GSK in the 4th quarter worth $40,000. PrairieView Partners LLC acquired a new position in GSK during the 2nd quarter valued at about $47,000. Finally, Triad Wealth Partners LLC acquired a new position in GSK during the 2nd quarter valued at about $49,000. 15.74% of the stock is owned by institutional investors.
GSK Stock Down 0.3 %
GSK stock opened at $42.43 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The business’s 50-day simple moving average is $41.30 and its two-hundred day simple moving average is $41.71. The company has a market cap of $87.94 billion, a PE ratio of 15.37, a PEG ratio of 1.41 and a beta of 0.66. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92.
GSK Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be paid a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.62%. GSK’s dividend payout ratio is presently 54.71%.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the company. Berenberg Bank raised GSK to a “strong-buy” rating in a research report on Thursday, June 20th. The Goldman Sachs Group assumed coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group upped their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK currently has a consensus rating of “Buy” and an average target price of $50.00.
Read Our Latest Analysis on GSK
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- What does consumer price index measure?
- How Much Can You Make in Stocks in One Month?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Why Invest in High-Yield Dividend Stocks?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.